Lexeo Therapeutics, Inc.(LXEO)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
LXEO Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Lexeo Therapeutics, Inc. (LXEO), a Healthcare sector company. LXEO is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Lexeo Therapeutics, Inc. reports net income of $-20.2M, free cash flow of $-21.2M. Top institutional holders of LXEO by reported 13-F value include Paradigm Biocapital Advisors, BlackRock,, Affinity Asset Advisors,, based on the most recent SEC filings. LXEO trades on the Nasdaq exchange and files with the SEC under CIK 1907108. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LXEO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Lexeo Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-20.2M
Free Cash Flow
Q1 2026
$-21.2M
Get alerted when LXEO's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Lexeo Therapeutics, Inc. including:
Top Institutional Holders of LXEO
Paradigm Biocapital Advisors LP
$35.5M6,184,134 shBlackRock, Inc.
$29.3M5,110,871 shAffinity Asset Advisors, LLC
$29.0M5,050,211 shRA CAPITAL MANAGEMENT, L.P.
$28.7M5,000,000 shJANUS HENDERSON GROUP PLC
$28.5M4,976,429 shVestal Point Capital, LP
$25.7M4,475,000 shFrazier Life Sciences Management, L.P.
$25.4M4,424,725 shCITADEL ADVISORS LLC
$22.0M3,834,999 shORBIMED ADVISORS LLC
$20.7M3,602,450 shSTATE STREET CORP
$20.5M3,568,242 sh
| Fund | Value | Shares |
|---|---|---|
| Paradigm Biocapital Advisors LP | $35.5M | 6,184,134 |
| BlackRock, Inc. | $29.3M | 5,110,871 |
| Affinity Asset Advisors, LLC | $29.0M | 5,050,211 |
| RA CAPITAL MANAGEMENT, L.P. | $28.7M | 5,000,000 |
| JANUS HENDERSON GROUP PLC | $28.5M | 4,976,429 |
| Vestal Point Capital, LP | $25.7M | 4,475,000 |
| Frazier Life Sciences Management, L.P. | $25.4M | 4,424,725 |
| CITADEL ADVISORS LLC | $22.0M | 3,834,999 |
| ORBIMED ADVISORS LLC | $20.7M | 3,602,450 |
| STATE STREET CORP | $20.5M | 3,568,242 |
More Healthcare Companies
View all Healthcare →Put LXEO on your watchlist
Track score changes the day Lexeo Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is LXEO a good stock to buy?
13F Pro's AI-powered analysis of Lexeo Therapeutics, Inc. (LXEO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LXEO are available on the LXEO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own LXEO?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LXEO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Lexeo Therapeutics, Inc.'s investment landscape.